autologous peripheral blood stem cell transplantation improves portal hemodynamics in patients with hepatitis b virusrelated decompensated cirrhosis

Chronic hepatitis b virus (hbv) infection may eventually lead to decompensated liver cirrhosis, which is a terminal illness. the aim of this study was to investigate the therapeutic efficacy of autologous peripheral blood stem cell (apbsc) transplantation to improve portal vein hemodynamics in patients with hbvrelated decompensated cirrhosis. this prospective study included 68 hospitalized patients who were diagnosed with hbvrelated decompensated cirrhosis. these patients were divided into two groups: the transplantation group included 33 patients, while the control group included 35. both groups received conventional medical treatment simultaneously, and apbsc transplantation was performed on the patients in the transplantation group. we evaluated the effects of apbsc transplantation on postoperative liver function using the following indices: total bilirubin, serum prothrombin and albumin, spleen size, and portal vein hemodynamics. postoperatively, all of the patients were followed up at 24, 36, and 48 weeks. the transplantation group had no serious reactions. compared with the control group, albumin and prothrombin activity in the transplantation group was significantly improved at 24, 36, and 48 weeks after the procedure, and spleen length and portal vein diameter were substantially reduced at 48 weeks. the velocity of peak portal vein blood flow and mean maximum portal vein blood flow were greatly increased in the apbsc transplantation group at 36 and 48 weeks, respectively; however, there was also decreased portal vein diameter, which reduced portal vein pressure in patients with hbvrelated decompensated cirrhosis. apbsc transplantation greatly benefits hbvlinked decompensated cirrhosis patients and should be recommended in clinical practice.